200,000+ products from a single source!

sales@angenechem.com

Home > Effects of PEGylated Fe–Fe3O4 core-shell nanoparticles on NIH3T3 and A549 cell lines

Effects of PEGylated Fe–Fe3O4 core-shell nanoparticles on NIH3T3 and A549 cell lines

 

B.H.  Domac a,1,  S.  AlKhatib b,1,  O.  Zirhli a,c,  N.G.  Akdogan d,  S¸ .C.  O€ çal  Dirican e,  G.  Bulut f, O. Akdogan


1.Introduction

Cancer is considered a major health problem around the world and many attempts have been made to minimize cancer incidence and mortality. Currently, several types of treatments are used for cancer therapy including surgery, radiation, chemotherapy, immunotherapy and targeted therapy, which focus on targeting specific genes and proteins that promote cancer growth and cancer cell survival [1].
Nanotechnology has recently arrived on the scene as a new field of science that opens enticing prospects of several applications, such as the treatment of various diseases including cancer [2]. Nanotechnology provides ways to enhance the efficacy of cancer therapies in targeting only malignant cells without damaging healthy cells [3]. One of the latest advances in nanotechnology is the development of numerous nanoparticle formulations that are engineered to be suitable for cancer research [4].

 

Nanoparticles (NP) have emerged as novel diagnostic and therapeutic tools for cancer due to their distinctive features in terms of size, shape, and surface characteristics. Organic nanoparticles, such as polymeric micelles, liposomes and dendrimers, and inorganic nanoparticles, such as magnetic NPs, gold NPs, and silica NPs have been used in a drug delivery system as drug carriers. According to the size and shape of nanoparticles, the delivered anti-cancer agents can target the tumor more specifically with fewer side effects and a higher treatment efficacy relies on enhanced permeability and retention (EPR) [5, 6, 7, 8].

 

Fe3O4 (magnetite) particles are heavily used in cancer diagnosis and treatment due to their biocompatibility and biodegradability. Risk and benefit requirements of magnetite particles make them indispensable for MRI contrast enhancement, targeted drug delivery, and magnetic hyperthermia applications [9, 10]. The latter application requires high coercivity and magnetization.
The size of the nanoparticles directly affects the duration of the NP in the blood circulation. Particles bigger than 200 nm are easily cleared by the reticuloendothelial system, albeit smaller particles are easily cleared by the body through the kidneys. Furthermore, hydrophobicity and negatively charged particles are easily detected and cleared by the mononuclear phagocyte system (MPS). Thereupon, appropriate coating  of the particles with synthetic polymers, surfactants, gold, silica, and peptides may be necessary [2].


Particles are generally coated with hydrophilic, uncharged and biocompatible coatings such as poly (ethylene glycol) (PEG) to prevent recognition by the MPS [11, 12, 13]. Thus, particles duration time in the blood circulation is extended. These nanoparticles reach a better performance for most of the aforementioned applications.
The effects of nanoparticles on living cells can vary depending on cell type, activity, type and size of the nanoparticle itself [14]. The aim of this study is to determine the effect of synthesized PEG-coated Fe/Fe3O4 nanoparticles on human non-small cell lung cancer A549 cells and mouse fibroblast NIH3T3 cells and evaluate their potential as anti-cancer agents. It is important to evaluate the toxicity of these nanoparticles by determining the half-maximal inhibitory concentration (IC50) on cultured cells. In parallel to this, cell proliferation assay, a widely applied method in nanotechnology to test the toxicity and effect of the nanoparticles on cell proliferation was performed [15]. Moreover, the possible effect of the nanoparticles on cell motility, which is a preliminary mechanism in cellular motility and the development of metastasis was analyzed through scratch assay [16].

 

2.Materials and methods

2.1.Nanoparticle  synthesis

Nanoparticles were produced via salt reduction, using the Y junction flow tube technique. FeCl2 and NaBH4 were used as the salt and the reducer, respectively. In a typical synthesis route, FeCl2 and NaBH4 are dissolved separately in 50 ml DI water and degassed for 30 min under N2 gas flow to get rid of free dissolved oxygen. The controllable mixture of these chemicals was assured by passing them through the Y junction flow tube (Figure 1). At the junction point, where the intermixing occurs, nanoparticles form and drop into the collection beaker. At this point, the particles get in touch with dissolved capping agents (surfactants, polymers, etc). In this study, PEG (10,000 MW) was used. PEG-coated Fe/ Fe3O4 nanoparticles were cleaned from byproducts (NaCl, etc) of the chemical reaction for four times and the final product was stored in pure EtOH. Two different types of nanoparticles have been synthesized by changing the NaBH4/FeCl2 molar ratio; NP1: 1.67 and NP2: 0.85.
Morphological, structural and magnetic characterization of the nanoparticles was performed by JEOL JEM-ARM200CFEG UHR-TEM, Bruker D2 Phaser XRD, and EZ9 Microsense VSM, respectively.

 

2.2.Cell culture

NIH3T3 mouse embryonic cells (CRL1658, ATCC) were grown in DMEM medium and A549 human non-small cell lung cancer cells (CCL185, ATCC) were grown in F12–K medium according to the manufacturer's protocol. All media were supplemented with 10% fetal bovine serum. Cells were maintained in 37 ○C humidified atmosphere with 5% CO2.

 

2.3.Dilution of nanoparticles

Nanoparticles were dissolved in DMSO at 2 mg/ml stock concentration and stored at room temperature.

 

2.4.Cell proliferation assay

Cellular proliferation was analyzed using WST-1 Reagent (Roche). Cells were seeded at a density of 10,000 cells/well for NIH3T3 and 5,000 cells/well for A549 in a 96-well plate. The next day, both NIH3T3 and A549 cells were treated with nanoparticles at different concentrations in triplicates. After 48h, 10μl of WST-1 reagent was added onto the cells and cells were incubated for 30mins. Absorbance values were measured at 420nm using MultiScan GO Microplate spectrophotometer. The IC50 values were determined by GraphPad Prism Software.

 

2.5.Scratch assay

The effect of the nanoparticles on cellular motility was assessed using the scratch assay. Cells were plated at a density of 400,000–600,000 cells/well on a 6-well plate in order to form a confluent monolayer the following day. After 24h, a scratch was made on the cell surface using a sterile p-200 pipette tip. The scratched plate was washed with PBS to remove non-adherent cells. The cells were then treated with the nanoparticles at concentrations that were folds of the relevant IC50 values (NIH3T3 cells at 13.75 μg/ml, 27.5 μg/ml, and 41.25 μg/ml concentrations and A549 cells at 0.5 μg/ml, 1 μg/ml, and 2 μg/ml concentrations) for an additional 48h. Images were captured using an Olympus CRKX41 inverted microscope at 24h and 48h of incubation. The distance of migrated cells compared to the baseline distance was measured in pixels. The numerical data obtained was analyzed by GraphPad Prism software
using“paired t-test (p < 0.05)”.

 

3.Results and discussion

3.1.Structural, morphological and magnetic characterization of nanoparticles

XRD analysis of NP1 and NP2 shows that the nanoparticles are composed of α-Fe and Fe3O4 (Magnetite) phases (Figure 2a). The average particle size of NP1: 21nm and NP2: 13nm has been predicted from Scherer's Eq. (D 0.9 λ/βcos θ, λ: wavelength, β: FWHM, θ: diffraction angle) by using the full width at half maximum of the highest peak in  XRD Data. Room temperature magnetic characterization reveals low magnetization and coercivity (Hc) of 350 Oe (Figure 2b). The high coercivity of these particles makes them suitable for hyperthermia ap- plications due to high hysteresis loss [10, 11].
In order to study the morphology of the particles, TEM study was performed. The bright-field TEM image of the particles shows spherical core-shell morphology, where the core is Fe with =20nm diameter, the shell is Fe3O4 with 3.5nm thickness (confirmed by energy dispersive x- ray spectroscopy) (Figure 3). Predicted values from the XRD data match with the size of the nanoparticles. Although PEG coating is not obvious in TEM bright-field images, PEG coating layer on the nanoparticles was realized due to the hydrophilic nature of the synthesized nanoparticles [2].

 

3.2.Cellular proliferation assay

Nanoparticles were dissolved in sterile DMSO and stored at room temperature. The stock concentration of the nanoparticles was prepared at 2 mg/ml. The final concentration of the DMSO administered on the cells was fixed at 0.1% due to the potential effect of this reagent on cell viability and proliferation.
NIH3T3 and A549 cells were treated with the NP1 at various concentrations (0–100 μg/ml). After incubation with the nanoparticles, 10μl of WST-1 reagent (Roche) was added onto the cells in order to check for the cell viability according to the manufacturer's protocol. The half- maximum inhibitory concentrations (IC50) of nanoparticles was found to be 27.5 μg/ml and 1 μg/ml in NIH3T3 and A549 cells, respectively. The cell viability versus log concentration plots are given in Figure 4.


3.3.Scratch assay

In order to test the potential of NP1 as an anti-cancer agent, scratch assay was performed on NIH3T3 and A549 cells. According to the data obtained on NIH3T3 cells, nanoparticles did not show a significant inhibitory role on cell motility when compared to the non-treated (negative control) cells both at 24 and 48 h of treatment (Figure  5). Cell death due to the toxic effect of NP1 on NIH3T3 cells was observed at
41.25 μg/ml concentration (two folds of the IC50 value) and 48h of treatment. On the contrary, nanoparticles had a significant inhibitory effect on the motility of A549 lung cancer cells when compared to the non-treated cells at 24 and 48 h of treatment (Figure 6).

 

4.Discussion

Although there have been many studies on effects of Fe3O4 nanoparticles in A549 cells [17, 18, 19, 20], to the best of our knowledge, there is no work related to the effects of Fe/Fe3O4 core-shell particles on these cells. Previous studies show concentration-dependent toxicity of Fe3O4 nanoparticles where a significant effect was observed only for concentrations of 100 μg/ml and higher [17, 18, 19]. Hence, particles are coated to reduce their potential toxic effects, so that they can be used with drugs in nanomedicine [18]. The toxicity of the magnetite nanoparticles is due to the increasing level of lipid peroxidation and decreasing antioxidant enzymes of human lung alveolar epithelial cells (A549), displaying a concentration-dependent toxicity in vitro [17].  Malvindi et. al. proposed that following the intake of nanoparticles by the cells, nanoparticles start to degrade and release Fe ions, which interact with hydrogen peroxide produced by the mitochondria. This process induces the generation of highly reactive hydroxyl radicals and ferric ions (Fe3 ) through the Fenton reaction. Therefore, hydroxyl radicals and ferric ions could damage DNA, leading to cell death [18].

 

In our study, contradictory to the aforementioned previous studies, it has been found that the synthesized particles are toxic at such low concentrations down to 1 μg/ml. In order to evaluate the cytotoxicity level of NP1 on A549 cells, an additional cytotoxicity experiment with a common chemotherapeutic agent, Paclitaxel was performed on the same cell line. The IC50 value of this drug on A549 cells was found to be 11.1 μg/ml (Figure 7). This data shows that NP1 with an IC50 value of 1 μg/ml is more toxic on A549 cells in comparison to Paclitaxel.
We explain the high toxicity of the nanoparticles via Fenton reaction; following the degradation of Fe3O4, Fe core is exposed which accelerates the release of Fe ions and this leads to cell death. In order to further prove this hypothesis, particles with a thicker Fe3O4 shell was also synthesized (NP2). The IC50 values of this thicker shelled nanoparticles were 29 μg/ ml and 27 μg/ml in NIH3T3 and A549 cells, respectively. The cell viability versus log concentrations are given in Figure 8. Surprisingly, no significant change was observed in NIH3T3 and A549 cell lines after treating them with thicker shelled nanoparticles in scratch assay (data not shown). As stated above, thicker Fe3O4 shell de-accelerates the degradation of the nanoparticles, consecutively slows down the  cell death process.

 

Rosman et al. recently evaluated the effects of Gallic acid (GA) on A549 cells. IC50 values found for GA, Fe3O4-PEG-GA and Doxorubicin were 56 μg/ml, 13 μg/ml and 0.58 μg/ml, respectively [20]. Synthesized NP1 nanoparticles in this study have a lower IC50 value (1 μg/ml) in comparison to GA coated nanoparticles. This data supports the hypothesis that NP1 is a promising nanoparticle that can be used as a potential anti-cancer agent.

 

5.Conclusions

In summary, Fe/Fe3O4 core/shell nanoparticles with an average size of 20 nm and 13 nm have been synthesized and their performance has been evaluated in vitro. The effect of the nanoparticles on proliferation/ survival and motility of NIH3T3 and A549 cells was assessed by cytotoxicity and scratch assays, respectively. IC50 value of NP1 was found to be 27.5 μg/ml in NIH3T3 and 1 μg/ml in A549 cells. This data indicates that the nanoparticles are more toxic to cancer cells. Comparatively, while the nanoparticles did not have any inhibitory effect on the motility of NIH3T3 cells, they showed a significant inhibitory effect on the motility of A549 lung cancer cells. The nanoparticles were found to be 100 times more toxic on cells when compared to the previous studies. This cellular phenomenon can be explained by the accelerated decomposition of particles due to the Fe core.

Angene offers products at competitive prices:

CAS No. 114095-06-6

Imidazo[1,2-a]quinoline-2-methanol, 7-ethyl-5-methoxy-

Catalog No.:AG000AKA MDL No.:

MF:C15H16N2O2 MW:256.2997

CAS No. 114095-26-0

Imidazo[1,2-a]pyridine, 8-[(4-azidophenyl)methoxy]-2,3-dimethyl-

Catalog No.:AG000AK9 MDL No.:

MF:C16H15N5O MW:293.3232

CAS No. 114095-72-6

Benzenemethanol, 3-methoxy-α-2-propen-1-yl-, 1-acetate

Catalog No.:AG000AK8 MDL No.:

MF:C13H16O3 MW:220.2643

CAS No. 114096-85-4

Benzene, 1-isocyanato-4-(2-isocyanatoethyl)-

Catalog No.:AG000AK7 MDL No.:

MF:C10H8N2O2 MW:188.1827

CAS No. 1141-05-5

1,2-Ethanediol, 1,2-di-2-pyridinyl-

Catalog No.:AG000AKL MDL No.:

MF:C12H12N2O2 MW:216.2359

CAS No. 1141-06-6

Ethanone, 2-hydroxy-1,2-di-2-pyridinyl-

Catalog No.:AG000AKK MDL No.:MFCD00010691

MF:C12H10N2O2 MW:214.2200

CAS No. 1141-07-7

Methanethione, (4-methoxyphenyl)phenyl-

Catalog No.:AG000AKJ MDL No.:

MF:C14H12OS MW:228.3095

CAS No. 1141-08-8

Methanethione, bis(4-methylphenyl)-

Catalog No.:AG000AKI MDL No.:

MF:C15H14S MW:226.3367

CAS No. 1141-23-7

Benzenepropanoic acid, β-(2-amino-2-oxoethyl)-4-chloro-

Catalog No.:AG000AKH MDL No.:MFCD00190251

MF:C11H12ClNO3 MW:241.6709

CAS No. 1141-24-8

Pentanedioic acid, 3-(4-bromophenyl)-

Catalog No.:AG000AKG MDL No.:MFCD09032971

MF:C11H11BrO4 MW:287.1066

CAS No. 1141-29-3

[1,1'-Biphenyl]-4-amine, 3'-nitro-

Catalog No.:AG000AKF MDL No.:

MF:C12H10N2O2 MW:214.2200

CAS No. 1141-33-9

2-Phenazinamine, 3,5-dihydro-3-imino-

Catalog No.:AG000AKE MDL No.:

MF:C12H10N4 MW:210.2346

CAS No. 1141-35-1

Benzoxazole, 2-(4-chlorophenyl)-

Catalog No.:AG000AKD MDL No.:MFCD00453917

MF:C13H8ClNO MW:229.6617

CAS No. 1141-38-4

2,6-NAPHTHALENEDICARBOXYLIC ACID

Catalog No.:AG000AKC MDL No.:MFCD00004105

MF:C12H8O4 MW:216.1895

CAS No. 1141-39-5

Ethanone, 1-(4'-amino[1,1'-biphenyl]-4-yl)-

Catalog No.:AG000AKB MDL No.:

MF:C14H13NO MW:211.2591

CAS No. 1141-45-3

Propanoic acid, 3-(2-naphthalenylthio)-

Catalog No.:AG000AL9 MDL No.:MFCD00051616

MF:C13H12O2S MW:232.2982

CAS No. 1141-54-4

2-Hepten-4-one, 2-methyl-6-(4-methylphenyl)-, (6R)-

Catalog No.:AG000AL8 MDL No.:

MF:C15H20O MW:216.3187

CAS No. 1141-58-8

Benzamide, N-(1-methyl-4-piperidinyl)-

Catalog No.:AG000AL7 MDL No.:

MF:C13H18N2O MW:218.2948

CAS No. 1141-59-9

1,3-Benzenediol, 4-[2-(2-pyridinyl)diazenyl]-

Catalog No.:AG000AL6 MDL No.:MFCD00006256

MF:C11H9N3O2 MW:215.2081

CAS No. 1141-70-4

1H-Pyrazole-5-carboxylic acid, 3-methyl-1-(phenylmethyl)-

Catalog No.:AG000AL5 MDL No.:MFCD01693537

MF:C12H12N2O2 MW:216.2359

CAS No. 1141-88-4

Benzenamine, 2,2'-dithiobis-

Catalog No.:AG000AL4 MDL No.:MFCD00007703

MF:C12H12N2S2 MW:248.3671

CAS No. 1141-92-0

Benzenesulfonamide, 4-(3-methylbutoxy)-

Catalog No.:AG000AL3 MDL No.:

MF:C11H17NO3S MW:243.3226

CAS No. 1141-93-1

Benzenesulfonamide, 4-hexyl-

Catalog No.:AG000AL2 MDL No.:

MF:C12H19NO2S MW:241.3498

CAS No. 1141-94-2

Benzenesulfonamide, 4-(pentyloxy)-

Catalog No.:AG000AL1 MDL No.:MFCD11213101

MF:C11H17NO3S MW:243.3226

CAS No. 114100-03-7

Phosphonic acid, [(2-methylphenyl)(methylthio)methyl]-, diethyl ester (9CI)

Catalog No.:AG000AL0 MDL No.:

MF:C13H21O3PS MW:288.3428

CAS No. 114100-07-1

1H-Pyrazole-4,5-dicarboxylic acid, 4,5-dihydro-, diethyl ester, trans- (9CI)

Catalog No.:AG000AKZ MDL No.:

MF:C9H14N2O4 MW:214.2185

CAS No. 114100-09-3

Methanesulfonamide, N-[3-(aminomethyl)phenyl]-

Catalog No.:AG000AKY MDL No.:MFCD05663962

MF:C8H12N2O2S MW:200.2581

CAS No. 114102-24-8

Benzoic acid, 2-[1-(acetyloxy)-2,4-hexadiynyl]-6-hydroxy-, methyl ester (9CI)

Catalog No.:AG000AKX MDL No.:

MF:C16H14O5 MW:286.2794

CAS No. 114102-28-2

L-Threoninamide, L-tyrosyl-L-prolyl-L-phenylalanyl- (9CI)

Catalog No.:AG000AKW MDL No.:

MF:C27H35N5O6 MW:525.5967

CAS No. 114102-89-5

β-D-Galactopyranoside, 2-nitrophenyl 6-O-(triphenylmethyl)-

Catalog No.:AG000AKV MDL No.:MFCD03701222

MF:C31H29NO8 MW:543.5639

CAS No. 114103-10-5

1,4-Dioxane-2-acetaldehyde, 2-(2-oxoethoxy)-, (S)- (9CI)

Catalog No.:AG000AKU MDL No.:

MF:C8H12O5 MW:188.1779

CAS No. 114105-63-4

Isoquinoline, 1,2,3,4-tetrahydro-6,7-dimethoxy-1-(1-methylethyl)-, (1S)-

Catalog No.:AG000AKT MDL No.:

MF:C14H21NO2 MW:235.3220

CAS No. 114106-25-1

Propane, 1,1'-sulfinylbis[3-chloro-

Catalog No.:AG000AKS MDL No.:

MF:C6H12Cl2OS MW:203.1299

CAS No. 114106-39-7

Phenol, 2-[1-(ethylthio)ethyl]-

Catalog No.:AG000AKR MDL No.:

MF:C10H14OS MW:182.2826

CAS No. 114106-77-3

2-Pentenedioic acid, 4-(methoxymethylene)-, 1,5-dimethyl ester, (2E,4Z)-

Catalog No.:AG000AKQ MDL No.:

MF:C9H12O5 MW:200.1886

CAS No. 114106-84-2

1-Pyrrolidinepropanoic acid, 2-(hydroxymethyl)-, methyl ester, (S)- (9CI)

Catalog No.:AG000AKP MDL No.:

MF:C9H17NO3 MW:187.2362

CAS No. 114107-02-7

2-Propanol, 1-fluoro-3-[(R)-(4-methylphenyl)sulfinyl]-, (2S)-

Catalog No.:AG000AKO MDL No.:

MF:C10H13FO2S MW:216.2724

CAS No. 114107-32-3

[1,1'-Biphenyl]-2-amine, 2',3,4',5-tetranitro-

Catalog No.:AG000AKN MDL No.:

MF:C12H7N5O8 MW:349.2127

CAS No. 114107-33-4

[1,1'-Biphenyl]-2-amine, 2',3,5,6'-tetranitro-

Catalog No.:AG000AKM MDL No.:

MF:C12H7N5O8 MW:349.2127

CAS No. 1141080-15-0

2H-Indol-2-one, 5-(3-chloro-4-fluorophenyl)-1,3-dihydro-3-methyl-3-(5-pyrimidinylmethyl)-1-(1H-1,2,4-triazol-5-yl)-

Catalog No.:AG000ALB MDL No.:MFCD22571548

MF:C22H16ClFN6O MW:434.8534

CAS No. 1141080-83-2

2H-Indol-2-one, 5-(3-chloro-4-fluorophenyl)-1,3-dihydro-3-Methyl-3-(5-pyriMidinylMethyl)-

Catalog No.:AG000ALA MDL No.:MFCD22572947

MF:C20H15ClFN3O MW:367.8040

CAS No. 114113-16-5

1H-Indole, 2-methoxy-1-methyl-

Catalog No.:AG000ALI MDL No.:MFCD12924797

MF:C10H11NO MW:161.2004

CAS No. 114113-27-8

2,3,5-Pyrrolidinetrione, 1-(4-methylphenyl)-4-(phenylmethylene)-, (Z)- (9CI)

Catalog No.:AG000ALH MDL No.:

MF:C18H13NO3 MW:291.3007

CAS No. 114113-28-9

2,3,5-Pyrrolidinetrione, 1-(4-methylphenyl)-4-(phenylmethylene)-, (E)- (9CI)

Catalog No.:AG000ALG MDL No.:

MF:C18H13NO3 MW:291.3007

CAS No. 114113-91-6

1,3-Dithiane, 4-butyl-2,2-dimethyl-, 3-oxide

Catalog No.:AG000ALF MDL No.:

MF:C10H20OS2 MW:220.3952

CAS No. 114113-99-4

Benzenemethanol, 3,5-dibromo-4-methoxy-

Catalog No.:AG000ALE MDL No.:MFCD12047705

MF:C8H8Br2O2 MW:295.9559

CAS No. 114114-06-6

2,3-Butanedione, 1-(phenylthio)-

Catalog No.:AG000ALD MDL No.:

MF:C10H10O2S MW:194.2502

CAS No. 114114-53-3

2H-Indol-2-one, 3-ethenyl-1,3-dihydro-3-hydroxy-

Catalog No.:AG000ALC MDL No.:

MF:C10H9NO2 MW:175.1840

© 2019 Angene International Limited. All rights Reserved.